Automated, Rapid, Point-of-Collection Flow Cytometry for Leukapheresis-Derived Starting Materials: Standardizing Immunophenotyping to Support Cell and Gene Therapy
Introduction – The Accellix Platform provides reliable results at the point of collection through automation, and operators require minimal training and no previous experience. We used a set of healthy donor leukopak samples to compare TBNK cell phenotyping results from the automated TBNK-16 (L) assay to a traditional flow cytometry method and found that cell frequencies correlated strongly, despite differences in instruments, workflow, panel design, and gating methods. Accellix TBNK-16 (L) assay was used to phenotype commercially-available reference material with low variability (CV < 7% across cell the cell phenotypes measured) and maintained accuracy and precision across different assay lots and operators. The Accellix Platform enables automated, standardized characterization of leukapheresis-derived starting material at the point of collection, minimizing process variability and subjective data analysis, and providing rapid leukopak phenotyping for cell therapy development and manufacturing.
Provide the following information and we’ll email you a copy of the poster:
*Required field
